Clemens Scherzer, MD
Head of the Neurogenomics Lab and the Parkinson Personalized Medicine Initiative at Harvard and Brigham and Womenís Hospital
Associate Professor of Neurology at Harvard Medical School
Co-Director, Biomarkers Program at Harvard NeuroDiscovery Center
Location: Boston, Massachusetts, United States
Clemens Scherzer, MD, is a physician-scientist at Harvard Medical School, where he serves as an associate professor of neurology, as well as at Brigham and Women's Hospital and at Massachusetts General Hospital. Scherzer leads the Neurogenomics Lab, Parkinson Personalized Medicine Program and the BRAINCODE project. He also co-directs the Biomarkers Program of the Harvard NeuroDiscovery Center, which he co-founded.
Scherzer uses genetic and "big data" methods to develop a new, proactive and personalized treatment for Parkinson's disease. He aims to study individuals' entire body to uncover unique features of their Parkinson's experience and match drugs and tests to these. This experimental approach, which researchers termed Parkinson's Discovery Engine, is powered by massive and diverse data generated from the Harvard Biomarkers Study.
Scherzer completed his neurology residency at Emory University and received the Dr. Paul Beeson and the George C. Cotzias Memorial Awards. He serves on the Steering Committee of the NIH Parkinson's Disease Biomarkers Program, the Vision Setting Panel of the Department of Defense Parkinson's Research Program and the Scientific Advisory Board of the American Parkinson Disease Foundation. He also serves on the editorial boards of the Neurogenetics and Biomarkers in Medicine journals.
- Searching for the Cause of Parkinsonís Disease in People with GBA Mutations (2017)
- Identification of Genetic Signatures in the Blood as Biomarkers for Parkinson's Disease (2016)
- GBA Meta-analysis Initiative: Charting a Path to Success for Clinical Trials in Patients with GBA-PD (2016)
- Contrasting Pathological Versus Normal Alpha-synuclein Assemblies (2014)
- Genetic Predictors of Prognosis: GBA and SNCA Meta-Analysis Project (2014)
- Probing Nurr1 Expression in Parkinsonís Disease (2014)
- Peripheral Blood-based Transcript Biomarkers for Prediction of Parkinson Disease in LRRK2 Mutation Carriers (2013)
- Alpha-Synuclein-Expression-Lowering Therapeutics: Initial Pre-Clinical Development (2013)
- From Genetic Risk Toward Genetic Prognosis (2013)
- Evaluation of PD-linked Transcripts in PPMI (2012)
- Unlimited Discovery of Non-Coding, Regulatory RNAs and Aberrant Splicing in Parkinson's (2011)
- Alpha-synuclein Expression Lowering therapeutics: Hit Confirmation (2011)
- Development and Initial Characterization of an Enzyme-linked Immunosorbent Assay for the Candidate PD Risk Marker ST13 (2007)
- Simple Blood Tests for Parkinson's Disease Derived from Genome-wide Expression Changes (2004)
- Gene Expression in Parkinson's Disease (2004)
- Simple Blood Tests for Parkinson's Disease Derived from Genome-wide Expression Changes (2002)